HMG-CoA reductase (atorvastatin component); CBD's cardiometabolic target not established

Class

Fixed-dose combination of atorvastatin (statin) and cannabidiol (CBD) — 'Statin+' platform, Indication Bioscience

Pathway

Atorvastatin inhibits hepatic cholesterol synthesis; CBD is combined to explore improved tolerability, not for additional lipid-lowering efficacy

HMG-CoA reductase is the rate-limiting enzyme in the mevalonate pathway, the route by which the liver manufactures cholesterol. Atorvastatin, a statin, blocks this enzyme, reducing cholesterol synthesis inside liver cells. In response, these cells display more LDL receptors on their surface, pulling more low-density lipoprotein cholesterol out of the bloodstream. Lowering LDL cholesterol this way is a long-established approach to reducing risk of atherosclerotic cardiovascular disease, and statins are a cornerstone of that therapeutic strategy. This fixed-dose combination pairs atorvastatin with cannabidiol (CBD), a non-psychoactive compound derived from cannabis. CBD is not intended to add cholesterol-lowering effect; it does not act on HMG-CoA reductase or related lipid pathways, and its specific cardiometabolic target has not been established. Rather, the rationale is tolerability: some patients on statins experience muscle-related discomfort that can lead to discontinuation, and CBD is being explored for anti-inflammatory and analgesic properties that might ease this burden. The combination therefore represents an attempt to preserve the proven lipid-lowering benefit of a statin while addressing a known adherence obstacle, rather than pursuing additional independent efficacy.